Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
FAQ Is Retatrutide 5 mg approved for general medical use
Not everyone needs the maximum 12 mg dose to achieve clinically meaningful weight loss
Understanding out-of-pocket costs for GLP-1 medications The list price is the price of the medication recommended by the manufacturer without any insurance coverage, discounts, or savings programs
You should avoid this medication if you: Have a personal or family history of medullary thyroid carcinoma (MTC) Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Are pregnant, planning to become pregnant, or breastfeeding Have a history of pancreatitis Have severe gastrointestinal conditions This is why working with a licensed medical providernot an online questionnairematters
US$ 26.06
US$ 23.61
US$ 29.89
US$ 21.56
